When it nabbed the first FDA approval for a retinal gene therapy in 2017, Spark Therapeutics helped launch a field of biotechs looking to treat eye diseases with a one-and-done medicine. No other retinal gene therapy biotech has followed in its regulatory footsteps since, but a cohort of startups in the field have emerged, giving Roche-owned Spark a litany of partnering options.
Swiss drugmaker Roche recorded impairment charges of 2.8 billion Swiss francs, or roughly $3 billion, in 2022 to account for falling sales forecasts for marketed cancer drugs as well as for gene therapies acquired via its 2019 deal for Spark Therapeutics.
Spark Therapeutics Enters Into Strategic Collaboration with Neurochase for Use of Proprietary Delivery Technology for CNS Disorders
An experimental gene therapy developed by Roche subsidiary Spark Therapeutics helped people with hemophilia maintain steady levels of a needed blood-clotting protein for up to five years after treatment, according to updated clinical trial results released Monday. The data suggest treatment could deliver long-lasting control over the bleeding disorder.
CAMBRIDGE, Mass., Oct. 4, 2022 /PRNewswire/ -- Chroma Medicine, Inc., (Chroma) a genomic medicine company pioneering single-dose epigenetic editing therapeutics, today announced the addition of Jeff Marrazzo, co-founder and former founding CEO of Spark Therapeutics, to its Board of Directors.
Roche’s gene therapy unit, Spark Therapeutics, and bluebird have jointly moved to dismiss the lawsuit thanks to a settlement agreement, according to a filing posted in a Delaware federal court.
Roche's gene therapy outfit Spark Therapeutics will get a fresh face April 1 as co-founding CEO Jeffrey Marrazzo steps down. Chief Operating Officer Ron Philip, a 10-year Pfizer veteran who joined Spark in 2017, will be Marrazzo's successor.
A federal judge in Delaware on Tuesday denied a request by Roche’s Spark Therapeutics unit for a preliminary injunction to temporarily block bluebird’s direct-to-consumer disease awareness project, dubbed “Be the Spark.”
Astellas is dishing out $18 million upfront and up to $1.6 billion in milestone and royalty payments to develop adeno-associated virus (AAV) vectors for gene therapies. The research tie-up follows a deal between Dyno and Roche and its Spark Therapeutics unit, which was disclosed last October and could balloon to above $1.8 billion.
Roche’s Spark Therapeutics unit is offering up to $328.5 million in biobucks for CombiGene’s gene therapy for epilepsy, which has a specific focus on drug-resistant forms of the condition.